Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Huang, Xiongfeng ^a   Wang, Jianmin ^a   Chen, Qiao ^a   Jiang, Jielin ^a  

^a JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DISTANT METASTASIS; HAZARD RATIO; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MEDIASTINAL LYMPH NODE SAMPLING; MEDIASTINUM LYMPH NODE; META ANALYSIS; METHODOLOGY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MEDIASTINUM; PATHOLOGY; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; MEDIASTINUM; NEOPLASM STAGING;

EID: 84907717264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109979     Document Type: Article

References (35)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
2. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, et al. (2009) Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14: 909-920.
3. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367-1380.
4. Xu F, Qi L, Yue D, Wang C (2013) The effect of the extent of lymph node dissection for stage IA non-small-cell lung cancer on patient disease-free survival. Clin Lung Cancer 14: 181-187.
5. Ou SH, Zell JA (2008) Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. J Thorac Oncol 3: 880-886.
6. Yang M, Cao H, Guo X, Zhang T, Hu P, et al. (2013) The number of resected lymph nodes (nLNs) combined with tumor size as a prognostic factor in patients with pathologic N0 and Nx non-small cell lung cancer. PLoS One 8: e73220.
7. Keller SM, Adak S, Wagner H, Johnson DH (2000) Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 70: 358-365; discussion 365-356.
8. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA (2006) Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 61: 597-603.
9. Manser R, Wright G, Hart D, Byrnes G, Campbell DA (2005) Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev: Cd004699.
10. Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, et al. (2011) Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 141: 662-670.
11. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8: 336-341.
12. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
13. Higgins JP, Green S, editors (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration.
14. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. Jama 295: 676-680.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj 327: 557-560.
16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
17. Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE 2nd, et al. (2006) Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 81: 1013-1019; discussion 1019-1020.
18. Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, et al. (1998) Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 227: 138-144.
19. Izbicki JR, Thetter O, Habekost M, Karg O, Passlick B, et al. (1994) Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial. Br J Surg 81: 229-235.
20. Sugi K, Nawata K, Fujita N, Ueda K, Tanaka T, et al. (1998) Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2cm in diameter. World J Surg 22: 290-294; discussion 294-295.
21. Wu Y, Huang ZF, Wang SY, Yang XN, Ou W (2002) A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 36: 1-6.
22. Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL (2003) Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 21: 1029-1034.
23. Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604-1608.
24. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, et al. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360.
25. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, et al. (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-2597.
26. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375: 1267-1277.
27. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Bmj 311: 899-909.
28. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, et al. (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559.
29. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, et al. (2005) Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23: 4999-5006.
30. Non-Small Cell Lung Cancer Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-4625.
31. Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, et al. (2005) Patterns of surgical care of lung cancer patients. Ann Thorac Surg 80: 2051-2056; discussion 2056.
32. Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, et al. (2002) Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 21: 520-526.
33. Lau J, Ioannidis JP, Schmid CH (1998) Summing up evidence: one answer is not always enough. Lancet 351: 123-127.
34. Mueller KF, Meerpohl JJ, Briel M, Antes G, von Elm E, et al. (2013) Detecting, quantifying and adjusting for publication bias in meta-analyses: protocol of a systematic review on methods. Syst Rev 2: 60.
35. Knobloch K, Yoon U, Vogt PM (2011) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Cra-niomaxillofac Surg 39: 91-92.